Перегляд вихідного коду сторінки What Precisely Is Happening With The PDK4

This can be accomplished if the analogues demonstrate similar chemical, physico-chemical and biological properties [2]. Given the vast experience with SST analogues that demonstrated variability of the biodistribution pattern dependent on the radiometal cation type and other chemical modifications [44], we preliminary compared the biodistribution of [68Ga]-DO3A-VS-Cys40-Exendin-4 and [177Lu]-DO3A-VS-Cys40-Exendin-4. The comparison of the radioactivity accumulation in the organs of interest investigated at 0.5 and 1 h time points demonstrated similar pattern for [68Ga]-DO3A-VS-Cys40-Exendin-4 and [177Lu]-DO3A-VS-Cys40-Exendin-4 with SUV [http://www.selleckchem.com/products/rgfp966.html RGFP966 clinical trial] might be extrapolated for the dosimetric calculations of [177Lu]-DO3A-VS-Cys40-Exendin-4. However, more thorough investigations are required in order to prove this concept. In addition, the dosimetric calculations in this study were conducted by extrapolation of [177Lu]-DO3A-VS-Cys40-Exendin-4 organ distribution performed in rats, however the absorbed doses of [68Ga]-DO3A-VS-Cys40-Exendin-4 were lower in pig, non-human primate and human as compared to rat [11,30,45,46], and since [177Lu]-DO3A-VS-Cys40-Exendin-4 follows the same biodistribution pattern, the rat data may underestimate the radioactivity dose that can safely be administered. [http://en.wikipedia.org/wiki/PDK4 PDK4] Figure 7 Organ distribution of [68Ga]-DO3A-VS-Cys40-Exendin-4 and [177Lu]-DO3A-VS-Cys40-Exendin-4 in male rats at 0.5 and 1 h p.i. BL: blood; LI: liver; PA: pancreas; SP: spleen; KI: kidneys. Conclusions The biodistribution of [177Lu]-DO3A-VS-Cys40-Exendin-4 in rat was studied as a function of time and the data was used for the calculation [http://www.selleckchem.com/products/pifithrin-alpha.html Pifithrin-�� cell line] of radiation dosimetry in humans. The blood clearance and elimination were fast without accumulation in organs including bone marrow. The dose-limiting organ was kidney with 3.8 GBq of [177Lu]-DO3A-VS-Cys40-Exendin-4 that could be injected before reaching the limit of 23 Gy. However, the preliminary estimation of the respective tumour absorbed dose indicated insufficient values that may render treatment futile. Hypothetically, the kidney protection and peptidase inhibition may allow reduction of kidney absorbed dose and amplification of the tumour absorbed doses. These means are required for possible use of [177Lu]-DO3A-VS-Cys40-Exendin-4 for the dosimetry guided fractionated radiotherapy of insulinomas. Acknowledgements Veronika Asplund is greatly acknowledged for the technical assistance. Olof Eriksson��s position is supported by ExoDiab and Ramkumar Selvaraju��s position is supported by Barn diabetesfonden and Diabetesfonden.